Fondation Eclosion is the life science incubator in Geneva who's mission is to foster entrepreneurs in translating their life science innovation into economic value and jobs. At Eclosion my main responsibility was to help entrepreneurs in Biotech/Pharma cross the so called "death valley".

DepGen SA is a biotech company focused on the creation of therapeutic monoclonal antibodies for the therapy of cancer. At DepGen my responsibility was drug discovery, from hit to final drug candidates.

- Project manager for an NBE. Coordination of teams/activities required for identification as well as biochemical and functional characterization of the lead candidate.- Responsible for NI-0401 nonclinical activities:....... - Supervisor of a Research Assistant for conducting relevant preclinical studies to support the development of NI-0401....... - Supervisor of a Ph.D. Student for investigating the biology of anti-CD3 antibodies in preclinical models of autoimmune and… Show more - Project manager for an NBE. Coordination of teams/activities required for identification as well as biochemical and functional characterization of the lead candidate.- Responsible for NI-0401 nonclinical activities:....... - Supervisor of a Research Assistant for conducting relevant preclinical studies to support the development of NI-0401....... - Supervisor of a Ph.D. Student for investigating the biology of anti-CD3 antibodies in preclinical models of autoimmune and inflammatory diseases- Supervision of the bioanalytical laboratory to support manufacturing activities associated with clinical development of NovImmune’s therapeutic monoclonal antibodies- Supervision of the clinical laboratory to support clinical development of NovImmune’s therapeutic monoclonal antibodies Show less

- Implemented a QA controlled bioanalytical laboratory to support preclinical (manufacturing potency assay) and clinical (biomarkers, PK, PD and Immunogenicity) development of therapeutic monoclonal antibodies- Characterized NI-0401 Pharmacokinetic, Pharmacodynamic and Immunogenicity in patients with moderate to severe active Crohn´s disease (Phase I/IIa) and patients with acute cellular renal allograft rejection (Phase IIa)- Responsible for experimental biology at Novimmune and… Show more - Implemented a QA controlled bioanalytical laboratory to support preclinical (manufacturing potency assay) and clinical (biomarkers, PK, PD and Immunogenicity) development of therapeutic monoclonal antibodies- Characterized NI-0401 Pharmacokinetic, Pharmacodynamic and Immunogenicity in patients with moderate to severe active Crohn´s disease (Phase I/IIa) and patients with acute cellular renal allograft rejection (Phase IIa)- Responsible for experimental biology at Novimmune and supervisor of a Ph.D. student validating therapeutic targets in preclinical models of autoimmune and inflammatory diseases Show less

- Implemented a laboratory for in vivo experimental biology (animal facility and histology lab) to support preclinical development of therapeutic monoclonal antibodies- Characterized NI-0401 pharmacodynamic effects in a relevant toxicology species (in vivo

- Managed a team that successfully produced a fully human therapeutic anti-CD3 monoclonal antibody (NI-0401)- Characterized NI-0401 biological properties (in vitro pharmacology)